Validation for microbiomes
With the first ever FDA approval for a faecal microbiome drug, the door has been opened for other microbiome approaches to follow. Yet the profile of Ferring Pharmaceuticals’ Rebyota leaves plenty of room for improvement by competitor products, such as Destiny’s NTCD-M3. If nothing else, with Destiny’s stated aim being a licensing deal for NTCD-M3, the FDA approval of Rebyota and the comparison with M3 should motivate its potential partners even more.After the FDA’s approval of Ferring Pharma’s Rebyota (fecal microbiota, live-jslm) the stage has been set for a new era of microbiome drug approvals. In many respects Rebyota has set a low bar for the competitor products that come after it, such as Destiny’s non-toxigenic Clostridioides difficile strain M3 (NTCD-M3).
Our valuation remains unchanged: we ascribe a fair value to Destiny Pharma of £251.2m or 345p per share.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.